Quest for the right Drug
נוסידקס NUSSIDEX (DEXCHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE AS HYDROCHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmacological properties : תכונות פרמקולוגיות
Pharmacodynamic Properties
5.1 Pharmacodynamic properties Dexchlorpheniramine Maleate ATC Code: R06AB02 Antihistamines for systemic use – substituted alkylamines. Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. H1- antagonists are structurally similar to anticholinergic agents and therefore possess the potential to exhibit anticholinergic properties of varying degrees. They also have antipruritic effects. Dexchlorpheniramine has high antihistaminic activity, moderate anticholinergic effects and minimal sedative effects. The medicine does not possess antiemetic properties. Pseudoephedrine ATC Code: R01BA02 Pseudoephedrine has direct and indirect sympathomimetic activity and is an orally effective upper respiratory tract decongestant. Pseudoephedrine is substantially less potent than ephedrine in producing both tachycardia and elevation of systolic blood pressure and considerably less potent in causing stimulation of the central nervous system.
Pharmacokinetic Properties
5.2 Pharmacokinetic Properties Dexchlorpheniramine Maleate The absorption, distribution, metabolism and elimination of dexchlorpheniramine have not been specifically described. However, since dexchlorpheniramine is the primary active isomer of the racemic compound chlorpheniramine, the pharmacokinetics of dexchlorpheniramine are likely to be similar to that of chlorpheniramine. Dexchlorpheniramine is administered orally. H1-antagonists are generally well absorbed from the GI tract. The onset of action of immediate release formulations of chlorpheniramine is about 30-60 minutes. The Cmax of chlorpheniramine occurs in about 2 hours, the maximum therapeutic effect in about 6 hours, and the duration of action lasts between 4-8 hours. Protein binding is approximately 72%. Chlorpheniramine is widely distributed in body tissues and fluids, and it crosses the placenta and is excreted into breast milk. The metabolism of chlorpheniramine is extensive and rapid, first occurring in the gastric mucosa and then on first-pass through the liver, which may be saturable. N-dealkylation produces several metabolites, which are excreted in the urine along with the parent compound. The half-life in healthy adults and children is 20-24 hours and 10-13 hours, respectively. Excretion rates are dependent on the pH of urine and urinary flow, with the rate decreasing as the pH rises and urinary flow decreases. Pseudoephedrine Pseudoephedrine is partly metabolised in the liver by N-demethylation to norpseudoephedrine, an active metabolite. Pseudoephedrine and its metabolite are excreted in the urine: 55% to 75% of a dose is excreted unchanged. The rate of urinary excretion of pseudoephedrine is accelerated when the urine is acidified. Conversely as the urine pH increases, the rate of urinary excretion is slowed.
שימוש לפי פנקס קופ''ח כללית 1994
Symptomatic treatment of common cold, allergic & vasomotor rhinits, hay fever
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
עלון מידע לצרכן
31.10.16 - עלון לצרכן 10.05.23 - עלון לצרכן עברית 21.08.23 - עלון לצרכן אנגלית 21.08.23 - עלון לצרכן עברית 21.08.23 - עלון לצרכן ערבית 29.01.24 - עלון לצרכן עברית 12.02.24 - עלון לצרכן אנגלית 12.02.24 - עלון לצרכן עברית 12.02.24 - עלון לצרכן ערבית 19.03.24 - עלון לצרכן עברית 13.05.24 - עלון לצרכן אנגלית 13.05.24 - עלון לצרכן עברית 13.05.24 - עלון לצרכן ערבית 31.07.24 - עלון לצרכן עברית 20.09.24 - עלון לצרכן אנגלית 20.09.24 - עלון לצרכן ערבית 26.09.24 - עלון לצרכן עברית 10.05.23 - החמרה לעלון 28.12.23 - החמרה לעלון 29.01.24 - החמרה לעלון 19.03.24 - החמרה לעלון 31.07.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
נוסידקס
